Pre-market hot trades in US stocks: Focus Universal up 8.57% in pre-market, Nasdaq compliance progress boosts market confidence

Pre-market Hot Trades in US Stocks Focus Universal rose 8.57% in pre-market trading. Based on recent news, On December 23, Focus Universal released its latest announcement through the EDGAR system, disclosing the company's financial and operational status. The announcement indicated that the company had made progress in meeting Nasdaq compliance requirements, boosting market confidence and driving up the stock price. On December 22, Focus Universal received a conditional compliance letter from Nasdaq. Nasdaq notified the company that its market capitalization was below $35 million, failing to meet key requirements, but granted conditional compliance based on the company meeting $2.5 million in shareholder equity. This news alleviated market concerns about the company's delisting risk, further driving up the stock price. On December 22, although Focus Universal still needs to prove continued compliance in its next regular filing to maintain its listing on the Nasdaq capital market, the potential delisting risk faced by the company and its shareholders has decreased. This news made investors more optimistic about the company's prospects, resulting in a stock price increase. The technology and electronics industry has performed strongly recently, with positive market sentiment. Top Gainers in Pre-market US Stocks Can-Fite rose 59.51% in pre-market trading. Based on recent key news: On December 24, Can-Fite BioPharma announced a 1-for-3000 reverse stock split, causing the stock price to drop 29% in after-hours trading. This move aims to adjust the ratio of ADS to common stock, affecting investor confidence. On December 26, Can-Fite BioPharma received a patent granted by the Brazilian Patent Office for an A3 adenosine receptor agonist for the treatment of sexual dysfunction, enhancing the company's global patent portfolio and driving up the stock price. On December 24, Can-Fite BioPharma's stock hit a 52-week low in regular trading, with a year-to-date decline of 85%, reflecting market concerns about the company's prospects. The biotechnology industry has been quite volatile recently and requires attention. A SPAC III Acquisition rose 46.13% in pre-market trading, with no significant news recently. The trading is active, with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Northann rose 36.09% in pre-market trading. Based on recent news, On December 23, Northann Corp. released its latest announcement through the EDGAR system, detailing the company's recent financial status and future development plans. This announcement boosted market confidence, leading to a significant rise in the stock price. On December 24, DBS analyst Pei Hwa Ho reiterated a buy rating on Northann Corp. and set a target price of SGD 1.25. The analyst's positive assessment further enhanced investor confidence, driving up the stock price On December 24th, market technical signals indicated a sell sentiment, but due to the positive impact of company announcements and analyst ratings, the stock price still rose significantly. Market sentiment is positive, and investor confidence has strengthened